Immuneering EBIT

Immuneering (IMRX) currently reports a EBIT of $-30B as of June 2026. That compares with $-31B in the prior-year period — up 1.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Immuneering's EBIT history and peer comparisons.

Immuneering's EBIT increased from $-31B to $-30B — a 1.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immuneering's EBIT of $-30B is lower than the Healthcare sector average of $23B. That is roughly 232.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Immuneering reported $-30B in EBIT as of June 2026. That compares with $-31B in the prior-year period — up 1.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-30B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Immuneering, and consider following IMRX for alerts when major investors trade the stock.